Pomerantz Law Firm Launches Dual Investigations into EHC and VSCO

The announcement by Pomerantz Law Firm of dual investigations into Encompass Health Corporation (EHC) and Victoria’s Secret & Co. (VSCO) underscores a tightening environment for corporate disclosure and the increasing speed of the securities litigation lifecycle. Pomerantz, a preeminent firm in the field of institutional and retail investor rights, is currently evaluating whether these companies or their officers engaged in securities fraud or other unlawful business practices. These investigations are typically the precursor to class-action litigation, aimed at recovering losses for shareholders who purchased stock during periods of allegedly misleading guidance.

For Encompass Health Corporation, the investigation follows a series of significant regulatory filings in early 2026. On March 10, 2026, the company filed an 8-K with the SEC detailing the entry into a material definitive agreement and the creation of a direct financial obligation. In the high-stakes world of healthcare services, where Encompass operates as a leader in integrated post-acute care, such financial shifts are scrutinized heavily for their impact on long-term solvency and shareholder equity. The investigation likely centers on whether the company's prior statements regarding its financial health and debt obligations were consistent with the reality of these new agreements.

“

The announcement by Pomerantz Law Firm of dual investigations into Encompass Health Corporation (EHC) and Victoria’s Secret & Co.

Simultaneously, Victoria’s Secret & Co. is facing scrutiny following its March 5, 2026, disclosure of operations and financial condition. Retail entities like VSCO are particularly vulnerable to securities litigation when earnings guidance or inventory management reports deviate significantly from previous executive projections. In the current economic climate, where consumer discretionary spending is volatile, any perceived lack of transparency regarding margin compression or supply chain health can lead to immediate legal challenges. The Pomerantz probe will examine if VSCO executives withheld material information that would have altered the investment profile for shareholders prior to the March disclosure.